Home/Pipeline/NPRL2 Gene Therapy

NPRL2 Gene Therapy

Solid Tumors (e.g., KRAS/STK11 NSCLC)

Preclinical/ResearchActive

Key Facts

Indication
Solid Tumors (e.g., KRAS/STK11 NSCLC)
Phase
Preclinical/Research
Status
Active
Company

About Genprex

Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.

View full company profile

Therapeutic Areas